论文部分内容阅读
目的评估我院口服降糖药的应用状况,为临床合理用药提供参考。方法采用药物限定日剂量(DDD值)分析方法,统计我院2006—2008年口服降糖药的用药频度(DDDs)、销售金额、每日药费(DDC)等数据。结果二甲双胍、瑞格列奈、阿卡波糖、格列美脲、格列奇特缓释片、罗格列酮钠片的DDDs逐年增长,销售金额亦呈增长趋势,DDDs排名前3位的是二甲双胍、瑞格列奈、阿卡波糖;销售金额排名前3位的是瑞格列奈、二甲双胍、阿卡波糖。销售金额序号与DDDs序号比值在0.5~2.2之间。结论二甲双胍、瑞格列奈、阿卡波糖在我院口服降糖药使用中占主导地位,尤其新品种在我院得到了广泛的应用。我院口服降糖药的使用基本合理。
Objective To evaluate the application of oral hypoglycemic agents in our hospital for reference for clinical rational drug use. Methods DDD value analysis method was used to calculate DDDs, sales amount and DDC of oral hypoglycemic agents in our hospital from 2006 to 2008. Results The DDDs of metformin, repaglinide, acarbose, glimepiride, glibenclamide and glipizide sodium tablets increased year by year, and the sales amount also showed an increasing trend. The top 3 DDDs were Metformin, repaglinide, acarbose; the top three sales amount is repaglinide, metformin, acarbose. The sales amount serial number and DDDs serial number ratio is between 0.5 ~ 2.2. Conclusion Metformin, repaglinide and acarbose dominate the use of oral hypoglycemic agents in our hospital, especially the new varieties have been widely used in our hospital. The use of oral hypoglycemic agents in our hospital is basically reasonable.